Scandion Oncology (Sweden) Today
| SCOL Stock | SEK 0.07 0 3.97% |
Performance0 of 100
| Odds Of DistressOver 68
|
Scandion Oncology is selling for under 0.0725 as of the 25th of November 2024; that is 3.97 percent down since the beginning of the trading day. The stock's last reported lowest price was 0.0695. Scandion Oncology has more than 68 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Scandion Oncology AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Scandion Oncology AS, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. The company was founded in 2017 and is based in Copenhagen, Denmark. Scandion Oncology operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. The company has 40.71 M outstanding shares. More on Scandion Oncology AS
Moving together with Scandion Stock
| 0.76 | CAMX | Camurus AB | PairCorr |
| 0.87 | HNSA | Hansa Biopharma AB | PairCorr |
| 0.9 | NANOFS | Nanoform Finland Plc | PairCorr |
Moving against Scandion Stock
Scandion Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Scandion Oncology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Scandion Oncology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Scandion Oncology AS (SCOL) is traded on Stockholm Exchange in Sweden and employs 14 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 111.79 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Scandion Oncology's market, we take the total number of its shares issued and multiply it by Scandion Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Scandion Oncology operates under Healthcare sector and is part of Biotechnology industry. The entity has 40.71 M outstanding shares.
Scandion Oncology AS has accumulated about 131.54 M in cash with (49.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Scandion Oncology Probability Of Bankruptcy
Ownership AllocationScandion Oncology shows a total of 40.71 Million outstanding shares. About 98.18 % of Scandion Oncology outstanding shares are held by general public with 1.82 (%) owned by insiders and only 0.0 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Scandion Ownership Details
Scandion Oncology Risk Profiles
Although Scandion Oncology's alpha and beta are two of the key measurements used to evaluate Scandion Oncology's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.62 | |||
| Standard Deviation | 5.19 | |||
| Variance | 26.88 | |||
| Risk Adjusted Performance | (0.15) |
Scandion Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Scandion Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
| All Next | Launch Module |
Scandion Oncology Corporate Management
Elected by the shareholders, the Scandion Oncology's board of directors comprises two types of representatives: Scandion Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scandion. The board's role is to monitor Scandion Oncology's management team and ensure that shareholders' interests are well served. Scandion Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scandion Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annie Rasmussen | Chief Director | Profile | |
| Morten Nissen | G Counsel | Profile | |
| Mads Kronborg | Head Communication | Profile | |
| Nils MD | Scientific CoFounder | Profile | |
| Johnny MS | CFO CEO | Profile | |
| Alfredo MD | Chief Officer | Profile |
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.